# Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
Canonical URL: https://biopharmsignal.com/news/TARS/tarsus-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-achievements
Ticker: TARS
Company: Tarsus Pharmaceuticals
Source: Tarsus Pharmaceuticals
Published: 2026-02-23 21:05 EST
Original Source URL: https://ir.tarsusrx.com
## Summary

Generated full-year 2025 net product sales of XDEMVY ® of $451.4 million, an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating leadership with initiation of Phase 2 trial of TP-04 in ocular rosacea (OR) and

## Article Body
Generated full-year 2025 net product sales of XDEMVY ® of $451.4 million, an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating leadership with initiation of Phase 2 trial of TP-04 in ocular rosacea (OR) and
## Recent Company News
- 2026-05-14 12:30 EST — [Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans](https://biopharmsignal.com/news/TARS/tarsus-and-john-cena-partner-to-raise-awareness-of-demodex-blepharitis-a-common-eyelid-disease-affecting-approximately-25-million-americans) — Source: Tarsus Pharmaceuticals
- 2026-05-06 20:05 EST — [Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements](https://biopharmsignal.com/news/TARS/tarsus-reports-first-quarter-2026-financial-results-and-recent-business-achievements) — Source: Tarsus Pharmaceuticals
- 2026-04-29 20:30 EST — [Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026](https://biopharmsignal.com/news/TARS/tarsus-to-report-first-quarter-2026-financial-results-on-wednesday-may-6-2026) — Source: Tarsus Pharmaceuticals
- 2026-03-31 12:30 EST — [Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease](https://biopharmsignal.com/news/TARS/tarsus-doses-first-participant-in-calliope-a-phase-2-clinical-trial-of-tp-05-lotilaner-a-novel-investigational-oral-tablet-for-the-potential-prevention-of-lyme-disease) — Source: Tarsus Pharmaceuticals
- 2026-03-23 12:30 EST — [TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus](https://biopharmsignal.com/news/TARS/tp-03-lotilaner-ophthalmic-solution-0-25-now-approved-in-china-for-the-treatment-of-demodex-blepharitis-triggering-a-15m-milestone-payment-to-tarsus) — Source: Tarsus Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)